Optiscan Imaging (OIL.AX) Azione Prezzo
Optiscan Imaging Prezzo
Il fatturato di Optiscan Imaging si è contratto del 12,5% all'anno negli ultimi 19 anni, scendendo a 448.769,00 AUD. Il margine netto di Optiscan Imaging si attesta al -1556,7%, in calo rispetto al -417,9% di alcuni anni fa.
Optiscan Imaging Prezzo delle azioni
Optiscan Imaging Azione e analisi azionaria
Domande frequenti sull'azione Optiscan Imaging
The business model of Optiscan Imaging Ltd focuses on developing and commercializing advanced medical imaging technologies. The company specializes in the design and manufacture of confocal laser endomicroscopes, which are used in various medical applications. Optiscan Imaging aims to improve the diagnosis and treatment of diseases through their innovative imaging solutions. By leveraging their expertise in advanced imaging technologies, the company aims to provide healthcare professionals with high-quality and real-time cellular imaging during medical procedures. Optiscan Imaging Ltd's business model is centered around offering cutting-edge medical imaging technologies that deliver precise and detailed cellular imaging for improved patient outcomes.
Optiscan Imaging Ltd is primarily active in the medical technology and healthcare industries.
The main competitors of Optiscan Imaging Ltd in the market include companies such as Carl Zeiss Meditec AG, NIDEK CO., LTD., and Topcon Corporation.
Optiscan Imaging Ltd is a renowned company specializing in medical imaging technologies. Established in [year], Optiscan has achieved significant milestones in the field of diagnostic imaging. The company is known for its innovative optical imaging systems, such as confocal microscopy, which provide high-resolution cellular images for diagnostic purposes. Optiscan Imaging Ltd has a rich history of research and development, consistently striving to push the boundaries of medical imaging. With its advanced imaging solutions, Optiscan continues to contribute to the progression of healthcare.
Optiscan Imaging Ltd has achieved several significant milestones. The company successfully developed and patented a revolutionary confocal endomicroscopy technology, which enables real-time, high-resolution imaging of living tissue. Optiscan Imaging Ltd also received clearance from the U.S. Food and Drug Administration (FDA) for its confocal endomicroscopy system, facilitating its entry into the American market. Furthermore, the company collaborated with renowned medical institutions and researchers worldwide to conduct clinical studies and validate the efficacy of its imaging technology. Optiscan Imaging Ltd's relentless dedication to innovation and research has positioned it as a leader in the field of real-time tissue imaging.
Optiscan Imaging Ltd is primarily present in Australia.
Optiscan Imaging Ltd is a company known for its strong commitment to innovation and excellence in medical imaging. With a vision to improve patient outcomes, Optiscan prides itself on providing cutting-edge solutions for real-time cellular imaging. The company's corporate philosophy revolves around leveraging advanced technology to enhance diagnostic accuracy and enhance the effectiveness of medical procedures. Optiscan Imaging Ltd values integrity, collaboration, and a customer-centric approach, ensuring that their products and services meet the evolving needs of the medical community. By prioritizing research and development, Optiscan aims to revolutionize the field of medical imaging, while maintaining a steadfast dedication to quality and patient care.
Convertita al tasso di cambio attuale, l’azione Optiscan Imaging quota 0,10 EUR (0,16 AUD).
L’azione Optiscan Imaging (OIL.AX) è quotata su 1 borse, tra cui: ASX (OIL.AX).
Optiscan Imaging Ltd is a leading provider of high-quality microscope systems and components for scientific research, medical diagnostics, and industrial testing and quality assurance. The company was founded in Melbourne, Australia in 1994 and has since expanded its operations worldwide. Today, Optiscan Imaging is a global company that delivers innovative technologies and products to meet the needs of its customers in various industries.
Il fatturato di Optiscan Imaging ammonta a 448.769,00 AUD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il profitto di Optiscan Imaging ammonta a -6,99 Mio. AUD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Optiscan Imaging è attualmente -23,91. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Optiscan Imaging.
Il rapporto prezzo/fatturato (P/S) di Optiscan Imaging è attualmente 372,28. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Optiscan Imaging.
Il Quality Score AlleAktien per Optiscan Imaging è 2/10.
L'ISIN di Optiscan Imaging è AU000000OIL4. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Optiscan Imaging è 932111. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Optiscan Imaging è OIL.AX. Con questo simbolo di borsa vengono negoziate le azioni Optiscan Imaging in borsa.
Azione Optiscan Imaging
Gruppo di pari di Optiscan Imaging
Optiscan Imaging Ticker
Optiscan Imaging FIGI
Altre metriche e analisi di Optiscan Imaging in Deep Dive.
La nostra analisi azionaria dell'azione Optiscan Imaging include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Optiscan Imaging. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: